Fundraising FoxGreen Meadow Ventures — 2017 Investments
1 investments dated 2017 · listed companies and verified rows first · show all
Angiexangiex.comin𝕏Jul 2017
Angiex develops Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) therapies for solid cancers, using a platform that delivers chemotherapeutic payloads to the nucleus of tumor cells and tumor blood vessel endothelial cells.
BiotechHealthtechMedical DevicesCambridge, US
Paul Jaminet(Founder & CEO)inShou-Ching Jaminet(Founder, Scientific Adviser)Hal Dvorak(Founder, SAB Chair)
BoardErrik Anderson(Director)Jason Camm(Director)inIain Dukes(Director)in
Co-investorsGaingelsK5 GlobalMana VenturesOrbiMed
__Twitter.png)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.